In the present study, to definitively assess these factors and analyze genomic fusions in an extensive and fully representative cohort, we searched for and identified BCR::ABL1 genomic breakpoints in 971 patients with BCR::ABL1-positive ALL (n = 519) and CML (n = 452). This evidence concerns the gene ABL1 and acute lymphoblastic leukemia.